Therefore, the FXR-ligands could be an effective therapeutic agent for fatty liver by affecting both lipid synthesis and degradation, in addition to the clinical benefits for the patients with PBC, NASH, and diabetes mellitus.(14–17). Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.